These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 37553597)

  • 1. BYL719 reverses gefitinib-resistance induced by PI3K/AKT activation in non-small cell lung cancer cells.
    Yu Y; Xiao Z; Lei C; Ma C; Ding L; Tang Q; He Y; Chen Y; Chang X; Zhu Y; Zhang H
    BMC Cancer; 2023 Aug; 23(1):732. PubMed ID: 37553597
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of the HSP27-AKT axis contributes to gefitinib resistance in non-small cell lung cancer cells independent of EGFR mutations.
    Choi SK; Kim M; Lee H; Kwon Y; Cha HJ; Jang SJ; Na Y; Lee YS
    Cell Oncol (Dordr); 2022 Oct; 45(5):913-930. PubMed ID: 35931945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polyphyllin II Restores Sensitization of the Resistance of PC-9/ZD Cells to Gefitinib by a Negative Regulation of the PI3K/Akt/mTOR Signaling Pathway.
    Zheng R; Jiang H; Li J; Liu X; Xu H
    Curr Cancer Drug Targets; 2017; 17(4):376-385. PubMed ID: 28093061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination therapy of gefitinib and miR-30a-5p may overcome acquired drug resistance through regulating the PI3K/AKT pathway in non-small cell lung cancer.
    Wang F; Meng F; Wong SCC; Cho WCS; Yang S; Chan LWC
    Ther Adv Respir Dis; 2020; 14():1753466620915156. PubMed ID: 32552611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 244-MPT overcomes gefitinib resistance in non-small cell lung cancer cells.
    Zhang Y; Yao K; Shi C; Jiang Y; Liu K; Zhao S; Chen H; Reddy K; Zhang C; Chang X; Ryu J; Bode AM; Dong Z; Dong Z
    Oncotarget; 2015 Dec; 6(42):44274-88. PubMed ID: 26517520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models.
    Qu Y; Wu X; Yin Y; Yang Y; Ma D; Li H
    J Exp Clin Cancer Res; 2014 Jun; 33(1):52. PubMed ID: 24939055
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced anticancer effect of the combination of BIBW2992 and thymidylate synthase-targeted agents in non-small cell lung cancer with the T790M mutation of epidermal growth factor receptor.
    Takezawa K; Okamoto I; Tanizaki J; Kuwata K; Yamaguchi H; Fukuoka M; Nishio K; Nakagawa K
    Mol Cancer Ther; 2010 Jun; 9(6):1647-56. PubMed ID: 20530710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Molecular mechanism of erlotinib resistance in epidermal growth factor receptor mutant non-small cell lung cancer cell line H1650].
    Han R; Wang X; Zhong D; Zhao J; Chen Z; Sun L; Wang J; Zhang J
    Zhongguo Fei Ai Za Zhi; 2012 Dec; 15(12):689-93. PubMed ID: 23249714
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blocking the PI3K/AKT and MEK/ERK signaling pathways can overcome gefitinib-resistance in non-small cell lung cancer cell lines.
    Li H; Schmid-Bindert G; Wang D; Zhao Y; Yang X; Su B; Zhou C
    Adv Med Sci; 2011; 56(2):275-84. PubMed ID: 22037177
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.
    Chen G; Kronenberger P; Teugels E; Umelo IA; De Grève J
    BMC Med; 2012 Mar; 10():28. PubMed ID: 22436374
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer.
    Engelman JA; Mukohara T; Zejnullahu K; Lifshits E; Borrás AM; Gale CM; Naumov GN; Yeap BY; Jarrell E; Sun J; Tracy S; Zhao X; Heymach JV; Johnson BE; Cantley LC; Jänne PA
    J Clin Invest; 2006 Oct; 116(10):2695-706. PubMed ID: 16906227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined inhibition of MEK and PI3K pathways overcomes acquired resistance to EGFR-TKIs in non-small cell lung cancer.
    Sato H; Yamamoto H; Sakaguchi M; Shien K; Tomida S; Shien T; Ikeda H; Hatono M; Torigoe H; Namba K; Yoshioka T; Kurihara E; Ogoshi Y; Takahashi Y; Soh J; Toyooka S
    Cancer Sci; 2018 Oct; 109(10):3183-3196. PubMed ID: 30098066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical rationale for PI3K/Akt/mTOR pathway inhibitors as therapy for epidermal growth factor receptor inhibitor-resistant non-small-cell lung cancer.
    Gadgeel SM; Wozniak A
    Clin Lung Cancer; 2013 Jul; 14(4):322-32. PubMed ID: 23332287
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway.
    Nguyen KS; Kobayashi S; Costa DB
    Clin Lung Cancer; 2009 Jul; 10(4):281-9. PubMed ID: 19632948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Curcumin overcome primary gefitinib resistance in non-small-cell lung cancer cells through inducing autophagy-related cell death.
    Chen P; Huang HP; Wang Y; Jin J; Long WG; Chen K; Zhao XH; Chen CG; Li J
    J Exp Clin Cancer Res; 2019 Jun; 38(1):254. PubMed ID: 31196210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Knockdown of the Bcl-2 gene increases sensitivity to EGFR tyrosine kinase inhibitors in the H1975 lung cancer cell line harboring T790M mutation.
    Zou M; Xia S; Zhuang L; Han N; Chu Q; Chao T; Peng P; Chen Y; Gui Q; Yu S
    Int J Oncol; 2013 Jun; 42(6):2094-102. PubMed ID: 23588221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BYL719, a selective inhibitor of phosphoinositide 3-Kinase α, enhances the effect of selumetinib (AZD6244, ARRY-142886) in KRAS-mutant non-small cell lung cancer.
    Ku BM; Jho EH; Bae YH; Sun JM; Ahn JS; Park K; Ahn MJ
    Invest New Drugs; 2015 Feb; 33(1):12-21. PubMed ID: 25342139
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins.
    Guix M; Faber AC; Wang SE; Olivares MG; Song Y; Qu S; Rinehart C; Seidel B; Yee D; Arteaga CL; Engelman JA
    J Clin Invest; 2008 Jul; 118(7):2609-19. PubMed ID: 18568074
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The PI3K/AKT pathway promotes gefitinib resistance in mutant KRAS lung adenocarcinoma by a deacetylase-dependent mechanism.
    Jeannot V; Busser B; Brambilla E; Wislez M; Robin B; Cadranel J; Coll JL; Hurbin A
    Int J Cancer; 2014 Jun; 134(11):2560-71. PubMed ID: 24374738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lymecycline reverses acquired EGFR-TKI resistance in non-small-cell lung cancer by targeting GRB2.
    Chen Y; Wu J; Yan H; Cheng Y; Wang Y; Yang Y; Deng M; Che X; Hou K; Qu X; Zou D; Liu Y; Zhang Y; Hu X
    Pharmacol Res; 2020 Sep; 159():105007. PubMed ID: 32561477
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.